HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis

Wang, Qiang; Zhang, Wei; Deng, Chao; Lin, Shicheng; Zhou, Yong

doi:10.3389/fonc.2022.1030825

Cited by 3 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study delves into the relationship between the long non-coding RNA (lncRNA) HOXA-AS2 in circulating tumor cells (CTCs) and the radiotherapy sensitivity of colorectal cancer. Previous research has substantiated the significant role of HOXA-AS2 in cancer [9][10][11][12][13][14] , with studies like that of Biyun Lu et al revealing its high expression correlating with poor prognosis and clinical pathological features in cancer patients [15] . In this study, researchers employed RT-PCR to precisely measure the expression levels of HOXA-AS2 in CTCs and cancer cells of patients with radiotherapy-sensitive and radiotherapytolerant colorectal cancer, uncovering its notably lower expression in the cancer tissues and CTCs of radiotherapy-sensitive patients.…”

Section: Discussionmentioning

confidence: 93%

Correlation Analysis between lncRNA HOXA-AS2 of Circulating Tumor Cells and Radiotherapy Sensitivity in Colon Cancer

2024

FMSR

View full text Add to dashboard Cite

The aim of this study is to analyze the association between lncRNA HOXA-AS2 in circulating tumor cells (CTC) and the radiotherapy sensitivity of colon cancer. The researchers detected the expression of HOXA-AS2 in cancer tissues and peripheral blood CTC of colon cancer patients with radiotherapy sensitivity and radiotherapy tolerance by RT-PCR method. Subsequently, radiotherapytolerant colon cancer cells were cultured in vitro, and HOXA-AS2 was silenced by cell transfection, followed by radiation therapy. The apoptosis of cells after radiotherapy was observed by MTT assay. The results showed that compared with radiotherapy-tolerant patients, HOXA-AS2 was significantly down-expressed in cancer tissues and CTC of radiotherapy-sensitive patients, and the difference was statistically significant (P<0.05). The radiotherapy sensitivity of colon cancer cells with silenced HOXA-AS2 was significantly improved, and the difference was also statistically significant (P<0.05). This indicates that the high expression of HOXA-AS2 in CTC is negatively associated with the radiotherapy sensitivity of colon cancer cells.

show abstract

Section: Discussionmentioning

confidence: 93%

Correlation Analysis between lncRNA HOXA-AS2 of Circulating Tumor Cells and Radiotherapy Sensitivity in Colon Cancer

2024

FMSR

View full text Add to dashboard Cite

show abstract

“…In updating the literature review to January 4, 2024, the present study incorporated the latest research findings on lncRNA HOXA-AS2, extending beyond the scope of previous meta-analyses (20,42,43). Unlike these prior studies, the present study provided an exhaustive subgroup analysis, considering six clinically relevant factors not previously analyzed together.…”

Section: Discussionmentioning

confidence: 99%

LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis

Xiao,

Yan,

Tan

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Elevated expression of long non-coding RNA homeobox A cluster antisense RNA 2 (lncRNA HOXA-AS2) is known to have prognostic value in various solid tumors. The present meta-analysis aimed to comprehensively quantify its prognostic significance across a wider spectrum of malignancies and to provide an updated synthesis of evidence that could refine prognostic models. To achieve this aim, multiple databases were carefully searched for lncRNA HOXA-AS2-related articles published in the past 10 years. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to demonstrate the prognostic value of lncRNA HOXA-AS2 using Stata 15.0 software. The function of lncRNA HOXA-AS2 was inferred from its associations with key clinical outcomes such as lymph node metastasis, distant metastasis, tumor stage and tumor size, which may reflect its role in tumor biology. In the present systematic review and meta-analysis of 454 patients across 7 studies, it was found that high lncRNA HOXA-AS2 expression was significantly associated with a shorter overall survival (OS) time in patients with cancer (HR=2.14; 95% CI, 1.40-3.27; P<0.001). High lncRNA HOXA-AS2 expression was also associated with lymph node metastasis [odds ratio (OR)=2.06; 95% CI, 1.07-3.99; P=0.032], distant metastasis (OR=2.11; 95% CI, 1.15-3.88; P=0.016), advanced tumor stage (OR=2.71; 95% CI, 1.50-4.89; P=0.001) and larger tumor size (OR=2.02; 95% CI, 0.86-4.78; P=0.006). However, no significant association was observed with age (OR=1.00; 95% CI, 0.63-1.59; P=0.991) or sex (OR=1.55; 95% CI, 0.72-3.34; P=0.258). In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA-AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these factors. This insight may direct future research to place more focus on the relationship between lncRNA HOXA-AS2 and specific cancer types and clinical characteristics.

show abstract

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis

Tew,

Kalfa,

Yang

et al. 2023

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Limited effective treatments are currently available for central nervous system (CNS) metastasis. This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated (ATM) inhibitor, as a radiosensitizer for breast cancer CNS metastasis treatment. Experimental Design: Three PDX tumors including 2 HER2+ and 1 triple negative breast cancer (TNBC) harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain. Results: Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared to 123 days in controls. Administration of AZD1390 post-treatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50-100 days post-treatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment. Conclusions: Our results demonstrate that AZD1390 effectively sensitizes breast cancer CNS metastasis to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CNS metastasis.

show abstract

HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis

Cited by 3 publications

References 65 publications

Correlation Analysis between lncRNA HOXA-AS2 of Circulating Tumor Cells and Radiotherapy Sensitivity in Colon Cancer

Correlation Analysis between lncRNA HOXA-AS2 of Circulating Tumor Cells and Radiotherapy Sensitivity in Colon Cancer

LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis

Contact Info

Product

Resources

About